Diurnal Group PLC Director Dealings (9260J)

TIDMDNL

RNS Number : 9260J

Diurnal Group PLC

16 April 2020

16 April 2020

Diurnal Group plc

("Diurnal" or the "Company")

Director Dealings

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings undertaken for tax planning purposes:

Richard Ross, Chief Scientific Officer sold 125,000 Ordinary Shares at a price of 30 pence per Ordinary Share; his and his wife's (Sarah Ross) respective ISAs purchased 125,000 Ordinary Shares in aggregate at a price of 30.02 pence per Ordinary Share. Following the transactions, the total beneficial interest of Richard Ross and his connected parties remains unchanged at 2,182,420 Ordinary Shares, representing 1.8% of the total voting rights as at 16 April 2020.

Details of the full notifications received by the Company are set out below:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                            Richard Ross 
      -----------------------------  --------------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------- 
 a)    Position/status                Chief Scientific Officer 
      -----------------------------  --------------------------------------------- 
 b)    Initial notification           Initial notification 
        /Amendment 
      -----------------------------  --------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------------------- 
 a)    Name                           Diurnal Group plc 
      -----------------------------  --------------------------------------------- 
 b)    LEI                            213800I2HNUNZN1LDH29 
      -----------------------------  --------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ---------------------------------------------------------------------------- 
 a)    Description of the             Ordinary shares of 5 pence each in 
        financial instrument,          Diurnal Group plc 
        type of instrument 
 
       Identification code            GB00BDB6Q760 
 
 b)    Nature of the transaction      Sale and purchase of ordinary shares 
      -----------------------------  --------------------------------------------- 
 c)    Price(s) and volume(s) 
                                            ---------------------  ---------- 
                                             Price(s)               Volume(s) 
                                            ---------------------  ---------- 
                                             Sale 30p               125,000 
     Purchase 30.02p                                                 62,500 
   --------------------------------------------------------------  ---------- 
 
 d)    Aggregated information 
 
  - Aggregated volume            As above 
 
  - Price 
 
 e)    Date of the transaction        16 April 2020 
      -----------------------------  --------------------------------------------- 
 f)    Place of the transaction       XLON 
      -----------------------------  --------------------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                Sarah Ross 
      ---------------------------------  ------------------------------------------------ 
 2     Reason for the notification 
      ----------------------------------------------------------------------------------- 
 a)    Position/status                    Closely associated person to an Executive 
                                           Director 
      ---------------------------------  ------------------------------------------------ 
 b)    Initial notification               Initial notification 
        /Amendment 
      ---------------------------------  ------------------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------------- 
 a)    Name                               Diurnal Group plc 
      ---------------------------------  ------------------------------------------------ 
 b)    LEI                                213800I2HNUNZN1LDH29 
      ---------------------------------  ------------------------------------------------ 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ----------------------------------------------------------------------------------- 
 a)    Description of the                 Ordinary shares of 5 pence each in 
        financial instrument,              Diurnal Group plc 
        type of instrument 
 
       Identification code                GB00BDB6Q760 
 
 b)    Nature of the transaction          Sale and purchase of ordinary shares 
      ---------------------------------  ------------------------------------------------ 
 c)    Price(s) and volume(s) 
                                          ----------------------------  --------------- 
                                           Price(s)                      Volume(s) 
                                          ----------------------------  --------------- 
    Purchase 30.02p                                                      62,500 
   -------------------------------------------------------------------  --------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                As above 
 
  - Price 
 
 e)    Date of the transaction            16 April 2020 
      ---------------------------------  ------------------------------------------------ 
 f)    Place of the transaction           XLON 
      ---------------------------------  ------------------------------------------------ 
 
 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                   [phone] 
 Diurnal Group plc                                  1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    [phone] 
  and Joint Broker)                                 2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: James Stearns 
 
                                                   [phone] 
 Cantor Fitzgerald Europe (Joint Broker)            7000 
 Corporate Finance: Phil Davies, Will Goode, 
  Luke Philippou 
 Healthcare Equity Sales: Andrew Keith 
 
                                                   [phone] 
 FTI Consulting (Media and Investor Relations)      1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHFLFFVSLIRLII

(END) Dow Jones Newswires

April 16, 2020 09:23 ET (13:23 GMT)